Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines, primarily using allogeneic mesenchymal stem cells like Lomecel-B. Its focus includes treatments for hypoplastic left heart syndrome, Alzheimer’s disease, and aging-related frailty. The company aims to advance cell therapies through clinical trials, leveraging proprietary technologies and strategic collaborations to address unmet medical needs in regenerative medicine.
This description was generated via AI from an annual report. Updated about 1 year ago.